Literature DB >> 9787144

Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease.

H T Greinix1, B Volc-Platzer, W Rabitsch, B Gmeinhart, C Guevara-Pineda, P Kalhs, J Krutmann, H Hönigsmann, M Ciovica, R M Knobler.   

Abstract

Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing compound 8-methoxypsoralen and ultraviolet A radiation has been shown to be effective in the treatment of several T-cell-mediated diseases, including cutaneous T-cell lymphoma and rejection after organ transplantation. We present 21 patients (10 men and 11 women) with hematological malignancies with a median age of 36 years (range, 25 to 55 years) who had received marrow grafts from sibling (n = 12) or unrelated (n = 9) donors. Six patients had acute graft-versus-host disease (GVHD) grade II to III not responding to cyclosporine A (CSA) and prednisolone when referred to extracorporeal photochemotherapy (ECP). In 15 patients, 2 to 24 months after bone marrow transplantation (BMT), extensive chronic GVHD with involvement of skin (n = 15), liver (n = 10), oral mucosa (n = 11), ocular glands (n = 6), and thrombocytopenia (n = 3) developed and was unresponsive to conventional therapy, including steroids. All patients were treated with ECP on 2 consecutive days every 2 weeks for the first 3 months and thereafter every 4 weeks until resolution of GVHD. ECP was tolerated excellently without any significant side effects. After a median of 14 cycles of ECP, acute GVHD resolved completely in 4 of 6 patients (67%) and partially in another 2 patients. Cutaneous chronic GVHD completely resolved in 12 of 15 (80%) patients. Contractures of knees and elbows due to scleroderma resolved partially. Oral mucosal ulcerations resolved in all patients. Seven of 10 patients (70%) with liver involvement had complete responses after ECP. After discontinuation of ECP, no severe infections were observed. Our findings suggest that ECP is a safe and effective adjunct therapy for both acute and extensive chronic GVHD with skin and visceral involvement and resistance to conventional therapy. Copyright 1998 by The American Society of Hematology

Entities:  

Mesh:

Year:  1998        PMID: 9787144

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

1.  Photopheresis at onset of type 1 diabetes: a randomised, double blind, placebo controlled trial.

Authors:  J Ludvigsson; U Samuelsson; J Ernerudh; C Johansson; L Stenhammar; G Berlin
Journal:  Arch Dis Child       Date:  2001-08       Impact factor: 3.791

Review 2.  Management of graft-versus-host disease in paediatric bone marrow transplant recipients.

Authors:  M Zecca; F Locatelli
Journal:  Paediatr Drugs       Date:  2000 Jan-Feb       Impact factor: 3.022

3.  Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD.

Authors:  Johannes K-H Meier; Daniel Wolff; Steve Pavletic; Hildegard Greinix; Martin Gosau; Hartmut Bertz; Stefanie J Lee; Anita Lawitschka; Sharon Elad
Journal:  Clin Oral Investig       Date:  2010-09-22       Impact factor: 3.573

4.  Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.

Authors:  Roger Belizaire; Haesook T Kim; Samuel J Poryanda; Nikola V Mirkovic; Evelyn Hipolito; William J Savage; Carol G Reynolds; Marie J Fields; Jennifer Whangbo; Tomohiro Kubo; Sarah Nikiforow; Edwin P Alyea; Philippe Armand; Corey S Cutler; Vincent T Ho; Bruce R Blazar; Joseph H Antin; Jerome Ritz; Robert J Soiffer; John Koreth
Journal:  Blood Adv       Date:  2019-04-09

Review 5.  [Extracorporeal photopheresis].

Authors:  U Just; R Knobler
Journal:  Hautarzt       Date:  2009-04       Impact factor: 0.751

6.  Guidelines on the use of extracorporeal photopheresis.

Authors:  R Knobler; G Berlin; P Calzavara-Pinton; H Greinix; P Jaksch; L Laroche; J Ludvigsson; P Quaglino; W Reinisch; J Scarisbrick; T Schwarz; P Wolf; P Arenberger; C Assaf; M Bagot; M Barr; A Bohbot; L Bruckner-Tuderman; B Dreno; A Enk; L French; R Gniadecki; H Gollnick; M Hertl; C Jantschitsch; A Jung; U Just; C-D Klemke; U Lippert; T Luger; E Papadavid; H Pehamberger; A Ranki; R Stadler; W Sterry; I H Wolf; M Worm; J Zic; C C Zouboulis; U Hillen
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-01       Impact factor: 6.166

7.  Extracorporeal photopheresis in the treatment of graft-versus-host disease: evidence and opinion.

Authors:  James W Hart; Lisa H Shiue; Elizabeth J Shpall; Amin M Alousi
Journal:  Ther Adv Hematol       Date:  2013-10

8.  Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease.

Authors:  Shinichiro Okamoto; Takanori Teshima; Mizuha Kosugi-Kanaya; Kaoru Kahata; Naomi Kawashima; Jun Kato; Takehiko Mori; Yukiyasu Ozawa; Koichi Miyamura
Journal:  Int J Hematol       Date:  2018-06-29       Impact factor: 2.490

9.  Extracorporeal photopheresis in the management of graft-versus-host disease.

Authors:  C Bredeson; R B Rumble; N P Varela; J Kuruvilla; C T Kouroukis
Journal:  Curr Oncol       Date:  2014-04       Impact factor: 3.677

Review 10.  Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation.

Authors:  Yoshihiro Inamoto; Nuria Valdés-Sanz; Yoko Ogawa; Monica Alves; Luigi Berchicci; John Galvin; Hildegard Greinix; Gregory A Hale; Biljana Horn; Debra Kelly; Hien Liu; Scott Rowley; Helene Schoemans; Ami Shah; Maria Teresa Lupo Stanghellini; Vaibhav Agrawal; Ibrahim Ahmed; Asim Ali; Neel Bhatt; Michael Byrne; Saurabh Chhabra; Zachariah DeFilipp; Kristina Fahnehjelm; Nosha Farhadfar; Erich Horn; Catherine Lee; Sunita Nathan; Olaf Penack; Pinki Prasad; Seth Rotz; Alicia Rovó; Jean Yared; Steven Pavletic; Grzegorz W Basak; Minoo Battiwalla; Rafael Duarte; Bipin N Savani; Mary E D Flowers; Bronwen E Shaw; Igor Petriček
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-24       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.